Gene Information
Gene symbol: MSH2
Gene name: mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)
HGNC ID: 7325
Synonyms: HNPCC, HNPCC1
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | ATM | 1 hits |
| 2 | BRCA1 | 1 hits |
| 3 | BRCA2 | 1 hits |
| 4 | CHEK2 | 1 hits |
| 5 | DCLRE1A | 1 hits |
| 6 | ERCC1 | 1 hits |
| 7 | FANCA | 1 hits |
| 8 | MLH1 | 1 hits |
| 9 | MSH6 | 1 hits |
| 10 | PALB2 | 1 hits |
| 11 | PARP1 | 1 hits |
| 12 | PMS2 | 1 hits |
| 13 | RAD51C | 1 hits |
| 14 | TIPARP | 1 hits |
| 15 | XPA | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 7987639 | Amongst the important known susceptibility genes are those dominant genes conferring a high risk of breast and ovarian cancer (BRCA1), colon cancer (hMSH2 and hMLH1), and melanoma (MLM). |
| 2 | 33426465 | Patients (N=37 349) had RS results of whom 714 had <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, <i>ATM</i>, <i>PALB2</i>, or Lynch syndrome (<i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i>) PVs. |
| 3 | 33426465 | For women aged 50 years or older at breast cancer diagnosis, RS often exceeded the chemotherapy benefit threshold (≥26) with <i>BRCA1</i> (71.7% vs 14.4% with none; <i>P</i> <.001), <i>PALB2</i> (37.1%; <i>P</i> = .001), and <i>BRCA2</i> (44.3%; <i>P</i> < .001) PVs. |
| 4 | 33426465 | PVs in <i>BRCA1</i>, but not <i>BRCA2</i>, <i>PALB2</i>, <i>ATM</i>, <i>CHEK2</i>, or Lynch syndrome genes, were associated with elevated RS on multivariable analysis (<i>P</i> < .001). |
| 5 | 33484353 | Mutation analysis of MLH1, MSH2, BRCA1 and BRCA2 genes showed pathogenic variants in 17/40 (42.5%) patients. |
| 6 | 35293552 | The following genes were selected: BRCA1, PALB2, RAD51C, BRCA2, ATM, FANCA, MSH2, XPA, ERCC1, PARP1, and SNM1. |
| 7 | 35293552 | The DNA expression of 2 genes assessed in pre-NACT biopsies (PALB2 and ERCC1) was lower in pCR than in non-pCR patients (P=0.005 and P=0.009, respectively). |
| 8 | 35293552 | The genes BRCA2 (P=0.009), ATM (P=0.004), FANCA (P=0.001), and PARP1 (P=0.011) showed a lower expression in post-NACT residual tumor samples (n=32) than in pre-NACT biopsy samples (n=98). |
| 9 | 35293552 | The expression of 2 genes (PALB2 and ERCC1) was lower in pCR patients. |